Main clinical and laboratory data on the studied patients
| Patient . | Age/sex . | Disease duration (mo) . | HCV genotype . | Previous therapies . | Main clinical features at baseline . | Serum laboratory features at baseline . | Follow-up after RTX (mo) . | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Cryo mg/dL . | RF IU/mL . | IgM g/L . | C4 mg/dL . | |||||||
| 1 | 58/M | 49 | 1b | IFN/Cy/CS/PF | Purpura, fever, arthralgias, nephritis | 90 | 868 | 1.7 | 8 | 15 |
| 2 | 67/F | 240 | ND | CS/PF | Purpura, urticaria | <50 | 42 | 1.0 | 2 | 31 |
| 3 | 68/F | 20 | HCV neg | CS/PF/IVIG | Purpura, skin ulcers, neuropathy | 1500 | 79 | 14.0 | 2 | 30 |
| 4 | 68/F | 72 | ND | CS | NHL, immune anemia, and neutropenia | 446 | 101 | 8.0 | 6 | 21 |
| 5 | 70/F | 132 | 2c | CS/AZA | Purpura, NHL, neuropathy, arteriopathy | 595 | 552 | 4.5 | 2 | 16 |
| 6 | 63/F | 36 | 1b | CS/IFN/IVIG/PF | Purpura, neuropathy | 2280 | 206 | 4.3 | 2 | 12 |
| 7 | 43/F | 168 | 1b | IFN/CS/Cy | Purpura, skin ulcers | 1305 | 197 | 1.6 | 2 | 12 |
| 8 | 62/M | 144 | 1b | CS/CVP/PF/IFN-R | NHL, hyperviscosity, astenia | +(NA) | 216 000 | 84.0 | NA | 19 |
| 9 | 66/F | 108 | HCV neg | AZA/Cy/CS/CSA/IFN | Purpura, neuropathy, arthralgias | 258 | 414 | 1.2 | 2 | 9 |
| 10 | 79/M | 84 | 2a2c | CS | Purpura, skin ulcers, neuropathy | 770 | 1920 | 1.1 | 6 | 9 |
| 11 | 63/F | 144 | 1b | IFN/PF/CS/IVIG | Neuropathy, nephritis | 2993 | 3700 | 4.4 | 12 | 9 |
| 12 | 73/F | 144 | ND | PF/IFN/CS/ 2-CdA | Purpura, skin ulcers | 60 | 26 | 1.7 | 3 | 9 |
| 13 | 69/F | 96 | 3a | IFN/CS/PF/IVIG | Purpura, skin ulcers, neuropathy | 1858 | 3080 | 3.8 | 8 | 9 |
| 14 | 64/M | 8 | HCV neg | CS | Purpura, neuropathy, arthralgias | 156 | 526 | 2.2 | 2 | 9 |
| 15 | 53/F | 192 | 2c | IFN/CS | Purpura, arthralgias | 2605 | 545 | 1.3 | 7 | 9 |
| Patient . | Age/sex . | Disease duration (mo) . | HCV genotype . | Previous therapies . | Main clinical features at baseline . | Serum laboratory features at baseline . | Follow-up after RTX (mo) . | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Cryo mg/dL . | RF IU/mL . | IgM g/L . | C4 mg/dL . | |||||||
| 1 | 58/M | 49 | 1b | IFN/Cy/CS/PF | Purpura, fever, arthralgias, nephritis | 90 | 868 | 1.7 | 8 | 15 |
| 2 | 67/F | 240 | ND | CS/PF | Purpura, urticaria | <50 | 42 | 1.0 | 2 | 31 |
| 3 | 68/F | 20 | HCV neg | CS/PF/IVIG | Purpura, skin ulcers, neuropathy | 1500 | 79 | 14.0 | 2 | 30 |
| 4 | 68/F | 72 | ND | CS | NHL, immune anemia, and neutropenia | 446 | 101 | 8.0 | 6 | 21 |
| 5 | 70/F | 132 | 2c | CS/AZA | Purpura, NHL, neuropathy, arteriopathy | 595 | 552 | 4.5 | 2 | 16 |
| 6 | 63/F | 36 | 1b | CS/IFN/IVIG/PF | Purpura, neuropathy | 2280 | 206 | 4.3 | 2 | 12 |
| 7 | 43/F | 168 | 1b | IFN/CS/Cy | Purpura, skin ulcers | 1305 | 197 | 1.6 | 2 | 12 |
| 8 | 62/M | 144 | 1b | CS/CVP/PF/IFN-R | NHL, hyperviscosity, astenia | +(NA) | 216 000 | 84.0 | NA | 19 |
| 9 | 66/F | 108 | HCV neg | AZA/Cy/CS/CSA/IFN | Purpura, neuropathy, arthralgias | 258 | 414 | 1.2 | 2 | 9 |
| 10 | 79/M | 84 | 2a2c | CS | Purpura, skin ulcers, neuropathy | 770 | 1920 | 1.1 | 6 | 9 |
| 11 | 63/F | 144 | 1b | IFN/PF/CS/IVIG | Neuropathy, nephritis | 2993 | 3700 | 4.4 | 12 | 9 |
| 12 | 73/F | 144 | ND | PF/IFN/CS/ 2-CdA | Purpura, skin ulcers | 60 | 26 | 1.7 | 3 | 9 |
| 13 | 69/F | 96 | 3a | IFN/CS/PF/IVIG | Purpura, skin ulcers, neuropathy | 1858 | 3080 | 3.8 | 8 | 9 |
| 14 | 64/M | 8 | HCV neg | CS | Purpura, neuropathy, arthralgias | 156 | 526 | 2.2 | 2 | 9 |
| 15 | 53/F | 192 | 2c | IFN/CS | Purpura, arthralgias | 2605 | 545 | 1.3 | 7 | 9 |
RF indicates rheumatoid factor (positive if ≥ 20 IU/mL); C4, complement C4 fraction (decreased if < 10 mg/dL); RTX, rituximab; IFN, interferon alpha; Cy, cyclophosphamide; CS, corticosteroids; PF, plasmapheresis; ND, not determined; IVIG, intravenous immunoglobulins; NHL, non-Hodgkin lymphoma; AZA, azathioprine; CVP, cyclophosphamide, vincristine, prednisone; R, ribavirin; NA, not available due to serum gelification; CSA, cyclosporin-A; and 2CdA, 2-Chlorodeoxyadenosyne.